In reply

Obstetrics and Gynecology

Volumn 117, Issue 2 PART 1, 2011, Pages 411-

  Grimes, David ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN;

BREAST CANCER; CODING; EPIDEMIOLOGICAL DATA; HUMAN; INFERTILITY; INTRAUTERINE CONTRACEPTIVE DEVICE; LETTER; ORAL CONTRACEPTION; PRIORITY JOURNAL; REGISTER; VENOUS THROMBOEMBOLISM;

EID: 79251558423     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318209703a     Document Type: Letter

References (7)

1. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339: b2890.
2. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboem-bolism: a five-year national casecontrol study. Contraception 2002;65:187-96.
3. Vlieg AvH, Helmerhorst FM, Vanden-broucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestagen type: results of the MEGA casecontrol study. BMJ 2009;339:b2921.
4. Nickelsen TN. [Data validity and coverage in the Danish National Health Registry. A literature review]. Ugeskr Laeger 2001;164:33-7.
5. Nielsen HW, Tuchsen F, Jensen MV. [Validity of the diagnosis "essential hypertension" in the National Patient Registry]. Ugeskr Laeger 1996;158:163-7.
6. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenonecontain-ing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54.
7. Kleinbaum DG, Kupper LL, Morgen-stern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold Company; 1982:91.